Ziopharm Oncology reported $-8396000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Amgen AMGN:US $ 3004M 337M
AstraZeneca AZN:LN 3562M 625M
Baxter International BAX:US $ 787M 124M
Biogen BIIB:US $ 1075.7M 401M
Bioline Rx BLRX:US $ -5.91M 0.52M
Bristol Myers Squibb BMY:US $ 5780M 8M
Corcept Therapeutics CORT:US $ 31.55M 4.49M
Curis CRIS:US $ -15.02M 0.08M
Eleven Biotherapeutics EBIO:US $ -0.82M 9.8M
Gilead Sciences GILD:US $ 2585M 837M
GlaxoSmithKline GSK:LN 2447M 673M
Intercept Pharmaceuticals ICPT:US $ -10.87M 0.98M
Johnson & Johnson JNJ:US $ 8036M 1273M
Karyopharm Therapeutics KPTI:US $ -42759000 8.35M
Novartis NOVN:VX SF 4660M 108M
Pfizer PFE:US $ 12921M 1739M
Ptc Therapeutics PTCT:US $ -63.18M 2.97M
Regeneron Pharmaceuticals REGN:US $ 1381.3M 20.4M
Sangamo Biosciences SGMO:US $ -42.85M 0.42M
Verastem VSTM:US $ -21.37M 4.42M
YTE INCY:US $ 276.8M 132.69M
Ziopharm Oncology ZIOP:US $ -8.4M 1.21M